Stroke patients show higher recovery in MultiStem therapy

February 24, 2016

Data presented by the biotech company Athersys indicate that stroke patients treated by an adult stem cell therapy called MultiStem did significantly better than others who received a placebo one year after treatment. The results are from a Phase 2 study involving clinical sites in the United States and the United Kingdom, including University Hospitals Case Medical Center. The study examined the safety and effectiveness of the new therapy developed for the treatment of ischemic stroke. The data were presented Feb. 17 at the 2016 International Stroke Conference in Los Angeles.

Of the 65 treated with MultiStem, 23.1 percent achieved a complete or near full recovery from their after one year. Only 8.2 percent of the 61 placebo patients achieved that level of recovery. Patients who received the cell therapy within 36 hours after the onset of stroke did even better, with 29 percent of those 31 patients achieving an excellent outcome.

Cathy Sila, MD, Director of the Comprehensive Stroke Center at UH Case Medical Center, and Professor of Neurology at Case Western Reserve University, was the principal investigator of the study at UH Case Medical Center.

"These results are very promising and this therapy would be an important adjunct to acute to reduce the amount of brain injury from which patients need to recover," said Dr. Sila. "But the results are still preliminary and need to be reproduced."

Since MultiStem therapy seems to be effective when given at 24 to 36 hours after the stroke, it means many more would be eligible for treatment, she said.

The video will load shortly

"Current therapy for stroke is unfortunately very limited. There is only one drug, tPA, that is FDA approved for , and tPA needs to be administered within hours of onset of a stroke," said Dr. Sila. "Despite public education and the development of , only about 7 percent of all patients nationwide receive tPA therapy and less than 2 percent undergo catheter-based clot removal . New treatments are needed to reverse the effects of a stroke and promote recovery from stroke, and they need to be effective in a wider time window to help more patients."

Ischemic stroke is caused by blockage in an artery in or to the brain, that impedes blood flow, and that can result in serious disability or even death.

MultiStem is a proprietary medication made by the Cleveland-based biotech company Athersys. The medication comes from a patented class of early adult stem cells called Multipotent Adult Progenitor Cells or MAPCs that are obtained from bone marrow. Hundreds of thousands to millions of doses can be made from the bone marrow cells of one donor. The cells do not come from the patient, so can be made in advance, stored in the hospital and be used off the shelf.

MultiStem cells appear to reduce the local inflammatory response and protect neurons in the brain, while modulating the body's general immune response and inflammation which leads to additional damage to the brain in the days immediately following the stroke. This is an entirely new concept for how cell therapies may provide benefit following central nervous system injury.

The Phase 2 study was double-blind (meaning both the patient and the doctors evaluating the patients didn't know which arm of the study the patient was in), randomized, and placebo-controlled. The study was funded by Athersys.

Explore further: Imaging, not time, may determine who is right for stroke clot removal

Related Stories

Quicker clot removal may lead to better outcomes

February 17, 2016

The faster a blood clot causing a stroke is removed, the less disability a patient may have, according to research presented at the American Stroke Association's International Stroke Conference 2016.

University of Kentucky offers stroke stem cell trial

January 13, 2012

The University of Kentucky will be the first site in the state and one of a select few in the entire country participating in the first stages of a groundbreaking study to investigate the effects of MultiStem, a human adult ...

Clot removal may save money and limit disability

February 17, 2016

Adding mechanical clot removal to clot-busting drugs could lower stroke survivors medical bills, decrease government healthcare as well as non-healthcare related costs, and increase the likelihood of the patient returning ...

Recommended for you

Engineers examine chemo-mechanics of heart defect

June 28, 2017

Elastin and collagen serve as the body's building blocks. They provide tensile strength and elasticity for a number of organs, muscles and tissues. Any genetic mutation short-circuiting their function can have a devastating, ...

Heart attack shown to be 'systemic condition'

June 28, 2017

An acute heart attack should not be viewed in isolation – myocardial infarction is a "systemic" condition with an impact upon the whole body and engenders responses in other organs, such as liver and spleen. That is the ...

Study identifies key player in heart enlargement

June 27, 2017

The heart is a dynamic muscle that grows and shrinks in response to stressors such as exercise and disease. The secret to its malleability lies in individual cells, which get bigger or smaller depending on the heart's needs. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.